Should patients with remnants from thyroid microcarcinoma really not be treated with iodine-131 ablation? (622 views)
Endocrine (ISSN: 1355-008x, 1355-008xlinking), 2013 Oct; 44(2): 426-433.
Export to BibTeX Export to EndNote
Paper type: Journal Article,
Impact factor: 3.527, 5-year impact factor: 2.675
Url: http://www.scopus.com/inward/record.url?eid=2-s2.0-84885644488&partnerID=40&md5=9d91573034fa829438d5a964e3907c5d
Keywords: Differentiated Thyroid Cancer, Low-Risk Patients, Microcarcinoma, Radioiodine Therapy, Remnant Ablation, Iodine 131, Levothyroxine, Radioactive Iodine, Thyroglobulin, Thyroid Hormone, Thyrotropin, Adolescent, Adult, Aged, Article, Cancer Incidence, Cancer Risk, Clinical Feature, Computer Assisted Tomography, Controlled Study, Cytology, Echography, Female, Fine Needle Aspiration Biopsy, Human, Major Clinical Study, Overall Survival, Physical Examination, Priority Journal, Retrospective Study, Single Photon Emission Computer Tomography, Thyroid Carcinoma, Thyroid Microcarcinoma, Thyroidectomy, Tumor Ablation, Whole Body Scintiscanning, Iodine Radioisotopes, Lymph Node Excision, Middle Aged, Neoplasm, Residual, Retrospective Studies, Thyroid Neoplasms, Emission-Computed, Single-Photon, X-Ray Computed, Treatment Outcome, Tumor Burden, Whole Body Imaging, Carcinoma Diagnosis Pathology Radiotherapy Surgery , Iodine Radioisotopes Therapeutic Use , Thyroid Neoplasms Diagnosis Pathology Radiotherapy Surgery,
Affiliations:
*** IBB - CNR ***
Istituto di Ricovero e Cura A Carattere Scientifico (IRCCS), Centro di Riferimento Oncologico di Basilicata (CROB), Via P. Pio 1, 85028 Rionero in Vulture, Italy
Istituto di Biostrutture e Bioimmagini, Consiglio Nazionale Delle Ricerche (CNR), Naples, Italy
References:
Not available.
Endocrine (ISSN: 1355-008x, 1355-008xlinking), 2013 Oct; 44(2): 426-433.
Export to BibTeX Export to EndNote
Paper type: Journal Article,
Impact factor: 3.527, 5-year impact factor: 2.675
Url: http://www.scopus.com/inward/record.url?eid=2-s2.0-84885644488&partnerID=40&md5=9d91573034fa829438d5a964e3907c5d
Keywords: Differentiated Thyroid Cancer, Low-Risk Patients, Microcarcinoma, Radioiodine Therapy, Remnant Ablation, Iodine 131, Levothyroxine, Radioactive Iodine, Thyroglobulin, Thyroid Hormone, Thyrotropin, Adolescent, Adult, Aged, Article, Cancer Incidence, Cancer Risk, Clinical Feature, Computer Assisted Tomography, Controlled Study, Cytology, Echography, Female, Fine Needle Aspiration Biopsy, Human, Major Clinical Study, Overall Survival, Physical Examination, Priority Journal, Retrospective Study, Single Photon Emission Computer Tomography, Thyroid Carcinoma, Thyroid Microcarcinoma, Thyroidectomy, Tumor Ablation, Whole Body Scintiscanning, Iodine Radioisotopes, Lymph Node Excision, Middle Aged, Neoplasm, Residual, Retrospective Studies, Thyroid Neoplasms, Emission-Computed, Single-Photon, X-Ray Computed, Treatment Outcome, Tumor Burden, Whole Body Imaging, Carcinoma Diagnosis Pathology Radiotherapy Surgery , Iodine Radioisotopes Therapeutic Use , Thyroid Neoplasms Diagnosis Pathology Radiotherapy Surgery,
Affiliations:
*** IBB - CNR ***
Istituto di Ricovero e Cura A Carattere Scientifico (IRCCS), Centro di Riferimento Oncologico di Basilicata (CROB), Via P. Pio 1, 85028 Rionero in Vulture, Italy
Istituto di Biostrutture e Bioimmagini, Consiglio Nazionale Delle Ricerche (CNR), Naples, Italy
References:
Not available.
Should patients with remnants from thyroid microcarcinoma really not be treated with iodine-131 ablation?
Remnant ablation by radioiodine is generally not recommended in patients presenting uni- or multifocal cancer <1 cm, in the absence of other higher risk features. We retrospectively studied low-risk patients (pts) with differentiated thyroid cancer (DTC) less than 1 cm recruited for radioiodine therapy (RAI). Methods: 91 pts (79 women, age 48.4 ± 12 yrs) with DTC were enrolled for RAI. Patients underwent pre-therapy ultrasonography (US), those with suspected/ambiguous lymph-nodes were excluded and proposed for cytology. Treated pts underwent post-therapeutic whole body scan (WBSt) completed by neck/chest SPECT/CT, when necessary (e.g. evidence of uptake outside of thyroid bed). A target lesion on SPECT/CT was defined as an identifiable lymph-nodal site presenting a matched significant iodine uptake. The patients were followed up for 14 ± 2 months thereafter. Results: All pts/cancers were pT1. The mean histological diameter was 0.68 ± 0.23 cm. Six patients were excluded because of suspected nodal involvement at US. Thirty (35 %) out of 85 pts had suspicious WBSt as per lymph-nodal involvement which was confirmed at the subsequent SPECT/CT acquisition in most part of pts (26/30; 86 %). Overall detected target lesions was 34, and nine (26 %) had interim positive fine needle cytology. Conclusions: a significant part of low risk DTC patients, for whom RAI is not recommended, presents an incidental suspicion of lymph-nodal involvement at WBSt confirmed by subsequent SPECT/CT. Such setting would have not been treated by I-131. © 2013 Springer Science+Business Media New York.
Remnant ablation by radioiodine is generally not recommended in patients presenting uni- or multifocal cancer <1 cm, in the absence of other higher risk features. We retrospectively studied low-risk patients (pts) with differentiated thyroid cancer (DTC) less than 1 cm recruited for radioiodine therapy (RAI). Methods: 91 pts (79 women, age 48.4 ± 12 yrs) with DTC were enrolled for RAI. Patients underwent pre-therapy ultrasonography (US), those with suspected/ambiguous lymph-nodes were excluded and proposed for cytology. Treated pts underwent post-therapeutic whole body scan (WBSt) completed by neck/chest SPECT/CT, when necessary (e.g. evidence of uptake outside of thyroid bed). A target lesion on SPECT/CT was defined as an identifiable lymph-nodal site presenting a matched significant iodine uptake. The patients were followed up for 14 ± 2 months thereafter. Results: All pts/cancers were pT1. The mean histological diameter was 0.68 ± 0.23 cm. Six patients were excluded because of suspected nodal involvement at US. Thirty (35 %) out of 85 pts had suspicious WBSt as per lymph-nodal involvement which was confirmed at the subsequent SPECT/CT acquisition in most part of pts (26/30; 86 %). Overall detected target lesions was 34, and nine (26 %) had interim positive fine needle cytology. Conclusions: a significant part of low risk DTC patients, for whom RAI is not recommended, presents an incidental suspicion of lymph-nodal involvement at WBSt confirmed by subsequent SPECT/CT. Such setting would have not been treated by I-131. © 2013 Springer Science+Business Media New York.
Should patients with remnants from thyroid microcarcinoma really not be treated with iodine-131 ablation?
No results. |
Should patients with remnants from thyroid microcarcinoma really not be treated with iodine-131 ablation?
Other filter: ([btitle,keywords] "Differentiated Thyro ...
Russo M, Malandrino P, Moleti M, Vermiglio F, D'Angelo A, La Rosa G, Sapuppo G, Calaciura F, Regalbuto C, Belfiore A, Vigneri R, Pellegriti G
* Differentiated thyroid cancer in children: Heterogeneity of predictive risk factors (399 views)
Pediatr Blood Cancer (ISSN: 1545-5009linking), 2018 Sep; 65(9): e27226-e27226.
Impact Factor: 2.513
View Export to BibTeX Export to EndNote
Mazziotti G, Formenti AM, Panarotto MB, Arvat E, Chiti A, Cuocolo A, Dottorini ME, Durante C, Agate L, Filetti S, Felicetti F, Filice A, Pace L, Pellegrino T, Rodari M, Salvatori M, Tranfaglia C, Versari A, Viola D, Frara S, Berruti A, Giustina A, Giubbini R
* Real-life management and outcome of thyroid carcinoma-related bone metastases: results from a nationwide multicenter experience (612 views)
Endocrine (ISSN: 1355-008x, 1355-008xlinking), 2017 Nov 06; 59(1): 90-101.
Impact Factor: 3.179
View Export to BibTeX Export to EndNote
Salvatore B, Klain M, Nicolai E, D'Amico D, De Matteis G, Raddi M, Fonti R, Pellegrino T, Storto G, Cuocolo A, Pace L
* Prognostic role of FDG PET/CT in patients with differentiated thyroid cancer treated with 131-iodine empiric therapy (760 views) (PDF 186 views)
Medicine (ISSN: 0025-7974), 2017 Oct; 96(42): e8344-e8344.
Impact Factor: 2.028
View Export to BibTeX Export to EndNote
Marotta V, Di Somma C, Rubino M, Sciammarella C, Modica R, Camera L, Del Prete M, Marciello F, Ramundo V, Circelli L, Buonomano P, Colao A, Faggiano A
* Second-line sunitinib as a feasible approach for iodine-refractory differentiated thyroid cancer after the failure of first-line sorafenib (451 views)
Endocrine (ISSN: 1355-008x), 2015 Aug; 49(3): 854-858.
Impact Factor: 3.279
View Export to BibTeX Export to EndNote
Pace L, Klain M, Salvatore B, Nicolai E, Zampella E, Assante R, Pellegrino T, Storto G, Fonti R, Salvatore M
* Prognostic Role of 18F-FDG PET/CT in the Postoperative Evaluation of Differentiated Thyroid Cancer Patients (591 views)
Clin Nucl Med (ISSN: 0363-9762, 1536-0229, 1536-0229electronic), 2015 Feb; 40(2): 111-115.
Impact Factor: 4.278
View Export to BibTeX Export to EndNote
Pace L, Klain M, Salvatore B, Nicolai E, Zampella E, Assante R, Pellegrino T, Storto G, Fonti R, Salvatore M
* Prognostic Role Of 18f-Fluorodeoxyglucose Positron Emission Tomography/Ct In The Postoperative Evaluation Of Differentiated Thyroid Cancer Patients (398 views)
Clin Nucl Med (ISSN: 0363-9762, 1536-0229, 1536-0229electronic), 2015 Feb; 40(2): 111-115.
Impact Factor: 4.278
View Export to BibTeX Export to EndNote
D'Antuono F, Gallicchio R, Venetucci A, Nardelli A, Giacomobono S, Pellegrino T, Tempone A, Di Leo A, Gattozzi D, Storto G
* Does remnant from differentiated thyroid microcarcinoma patients really not be treated with Iodine-131 ablation? (362 views)
Eur J Nucl Med (ISSN: 1619-7070, 1619-7089, 0340-6997), 2013 Oct; 40: N/D-N/D.
Impact Factor: 5.217
View Export to BibTeX Export to EndNote
Marotta V, Ramundo V, Camera L, Del Prete M, Fonti R, Esposito R, Palmieri G, Salvatore M, Vitale M, Colao A, Faggiano A
* Sorafenib in advanced iodine-refractory differentiated thyroid cancer: Efficacy, safety and exploratory analysis of role of serum thyroglobulin and FDG-PET (644 views)
Clin Endocrinol (ISSN: 0300-0664, 1365-2265, 1365-2265electronic), 2013 May; 78(5): 760-767.
Impact Factor: 3.353
View Export to BibTeX Export to EndNote
Barbato F, Capacchione D, Nappi A, Telesca D, Tempone A, Casolino E, Nardelli A, Castaldi E, Ortosecco G, Storto G
* Does remnants from low-risk differentiated thyroid cancer patients really be not treated with Iodine-131? (363 views)
Eur J Nucl Med (ISSN: 1619-7070, 1619-7089, 0340-6997), 2010 Oct; 37: N/D-N/D.
Impact Factor: 5.036
View Export to BibTeX Export to EndNote
Pace L, Nicolai E, Klain M, Salvatore M
* Diagnostic value of FDG PET/CT imaging (575 views)
Q J Nucl Med Mol Im (ISSN: 1824-4785, 1824-4478, 1824-4785linking), 2009; 53(5): 503-512.
Impact Factor: 1.724
View Export to BibTeX Export to EndNote
Salvatore B, Paone G, Klain M, Storto G, Nicolai E, D'Amico D, Della Morte AM, Pace L, Salvatore M
* Fluorodeoxyglucose PET/CT in patients with differentiated thyroid cancer and elevated thyroglobulin after total thyroidectomy and 131I ablation (844 views)
Q J Nucl Med Mol Im (ISSN: 1824-4785, 1824-4478, 1824-4785linking), 2008 Mar; 52(1): 2-8.
Impact Factor: 1.724
View Export to BibTeX Export to EndNote
Storto G, Liuzzi R, Klain M, Albanese C, Salvatore B, Pellegrino T, Cella L, Soricelli A, Pace L, Salvatore M
* Prognostic indicators in patients with differentiated thyroid cancer receiving repeated I-131 therapies (424 views)
Eur J Nucl Med (ISSN: 1619-7070, 1619-7089, 0340-6997), 2006 Sep; 33: N/D-N/D.
Impact Factor: 4.041
View Export to BibTeX Export to EndNote
Pace L, Klain M, Albanese C, Salvatore B, Storto G, Soricelli A, Salvatore M
* Short-term outcome of differentiated thyroid cancer patients receiving a second iodine-131 therapy on the basis of a detectable serum thyroglobulin level after initial treatment (532 views)
Eur J Nucl Med (ISSN: 1619-7070, 1619-7089, 0340-6997), 2006 Feb; 33(2): 179-183.
Impact Factor: 4.041
View Export to BibTeX Export to EndNote
Pace L, Klain M, Soricelli A, Albanese C, Salvatore B, Storto G, Salvatore M
* Short Term Outcome of Differentiated Thyroid Cancer Patients with Detectable Serum Thyroglobulin after Initial Treatment Receiving a Second 131-IODINE Therapy (522 views)
Eur J Nucl Med (ISSN: 1619-7070, 1619-7089, 0340-6997), 2005 Sep; 32: 179-183.
Impact Factor: 3.883
View Export to BibTeX Export to EndNote
Klain M, Pellegrino T, Storto G, Biondi B, Sansone V, Pagano L, Nicolai E, Della Morte A, D'Amico D, Soricelli A, Lombardi G, Pace L, Salvatore M
* Postsurgical follow up of differentiated thyroid cancer using rhTSH (378 views)
Eur J Nucl Med (ISSN: 1619-7070, 1619-7089, 0340-6997), 2004 Sep; 31: N/D-N/D.
Impact Factor: 3.935
View Export to BibTeX Export to EndNote
Biondi B, Palmieri EA, Pagano L, Klain M, Scherillo G, Salvatore M, Fenzi G, Lombardi G, Fazio S
* Cardiovascular safety of acute recombinant human thyrotropin administration to patients monitored for differentiated thyroid cancer (534 views)
J Clin Endocrinol Metab (ISSN: 0021-972x), 2003 Jan; 88(1): 211-214.
Impact Factor: 5.873
View Export to BibTeX Export to EndNote
* Differentiated thyroid cancer in children: Heterogeneity of predictive risk factors (399 views)
Pediatr Blood Cancer (ISSN: 1545-5009linking), 2018 Sep; 65(9): e27226-e27226.
Impact Factor: 2.513
View Export to BibTeX Export to EndNote
Mazziotti G, Formenti AM, Panarotto MB, Arvat E, Chiti A, Cuocolo A, Dottorini ME, Durante C, Agate L, Filetti S, Felicetti F, Filice A, Pace L, Pellegrino T, Rodari M, Salvatori M, Tranfaglia C, Versari A, Viola D, Frara S, Berruti A, Giustina A, Giubbini R
* Real-life management and outcome of thyroid carcinoma-related bone metastases: results from a nationwide multicenter experience (612 views)
Endocrine (ISSN: 1355-008x, 1355-008xlinking), 2017 Nov 06; 59(1): 90-101.
Impact Factor: 3.179
View Export to BibTeX Export to EndNote
Salvatore B, Klain M, Nicolai E, D'Amico D, De Matteis G, Raddi M, Fonti R, Pellegrino T, Storto G, Cuocolo A, Pace L
* Prognostic role of FDG PET/CT in patients with differentiated thyroid cancer treated with 131-iodine empiric therapy (760 views) (PDF 186 views)
Medicine (ISSN: 0025-7974), 2017 Oct; 96(42): e8344-e8344.
Impact Factor: 2.028
View Export to BibTeX Export to EndNote
Marotta V, Di Somma C, Rubino M, Sciammarella C, Modica R, Camera L, Del Prete M, Marciello F, Ramundo V, Circelli L, Buonomano P, Colao A, Faggiano A
* Second-line sunitinib as a feasible approach for iodine-refractory differentiated thyroid cancer after the failure of first-line sorafenib (451 views)
Endocrine (ISSN: 1355-008x), 2015 Aug; 49(3): 854-858.
Impact Factor: 3.279
View Export to BibTeX Export to EndNote
Pace L, Klain M, Salvatore B, Nicolai E, Zampella E, Assante R, Pellegrino T, Storto G, Fonti R, Salvatore M
* Prognostic Role of 18F-FDG PET/CT in the Postoperative Evaluation of Differentiated Thyroid Cancer Patients (591 views)
Clin Nucl Med (ISSN: 0363-9762, 1536-0229, 1536-0229electronic), 2015 Feb; 40(2): 111-115.
Impact Factor: 4.278
View Export to BibTeX Export to EndNote
Pace L, Klain M, Salvatore B, Nicolai E, Zampella E, Assante R, Pellegrino T, Storto G, Fonti R, Salvatore M
* Prognostic Role Of 18f-Fluorodeoxyglucose Positron Emission Tomography/Ct In The Postoperative Evaluation Of Differentiated Thyroid Cancer Patients (398 views)
Clin Nucl Med (ISSN: 0363-9762, 1536-0229, 1536-0229electronic), 2015 Feb; 40(2): 111-115.
Impact Factor: 4.278
View Export to BibTeX Export to EndNote
D'Antuono F, Gallicchio R, Venetucci A, Nardelli A, Giacomobono S, Pellegrino T, Tempone A, Di Leo A, Gattozzi D, Storto G
* Does remnant from differentiated thyroid microcarcinoma patients really not be treated with Iodine-131 ablation? (362 views)
Eur J Nucl Med (ISSN: 1619-7070, 1619-7089, 0340-6997), 2013 Oct; 40: N/D-N/D.
Impact Factor: 5.217
View Export to BibTeX Export to EndNote
Marotta V, Ramundo V, Camera L, Del Prete M, Fonti R, Esposito R, Palmieri G, Salvatore M, Vitale M, Colao A, Faggiano A
* Sorafenib in advanced iodine-refractory differentiated thyroid cancer: Efficacy, safety and exploratory analysis of role of serum thyroglobulin and FDG-PET (644 views)
Clin Endocrinol (ISSN: 0300-0664, 1365-2265, 1365-2265electronic), 2013 May; 78(5): 760-767.
Impact Factor: 3.353
View Export to BibTeX Export to EndNote
Barbato F, Capacchione D, Nappi A, Telesca D, Tempone A, Casolino E, Nardelli A, Castaldi E, Ortosecco G, Storto G
* Does remnants from low-risk differentiated thyroid cancer patients really be not treated with Iodine-131? (363 views)
Eur J Nucl Med (ISSN: 1619-7070, 1619-7089, 0340-6997), 2010 Oct; 37: N/D-N/D.
Impact Factor: 5.036
View Export to BibTeX Export to EndNote
Pace L, Nicolai E, Klain M, Salvatore M
* Diagnostic value of FDG PET/CT imaging (575 views)
Q J Nucl Med Mol Im (ISSN: 1824-4785, 1824-4478, 1824-4785linking), 2009; 53(5): 503-512.
Impact Factor: 1.724
View Export to BibTeX Export to EndNote
Salvatore B, Paone G, Klain M, Storto G, Nicolai E, D'Amico D, Della Morte AM, Pace L, Salvatore M
* Fluorodeoxyglucose PET/CT in patients with differentiated thyroid cancer and elevated thyroglobulin after total thyroidectomy and 131I ablation (844 views)
Q J Nucl Med Mol Im (ISSN: 1824-4785, 1824-4478, 1824-4785linking), 2008 Mar; 52(1): 2-8.
Impact Factor: 1.724
View Export to BibTeX Export to EndNote
Storto G, Liuzzi R, Klain M, Albanese C, Salvatore B, Pellegrino T, Cella L, Soricelli A, Pace L, Salvatore M
* Prognostic indicators in patients with differentiated thyroid cancer receiving repeated I-131 therapies (424 views)
Eur J Nucl Med (ISSN: 1619-7070, 1619-7089, 0340-6997), 2006 Sep; 33: N/D-N/D.
Impact Factor: 4.041
View Export to BibTeX Export to EndNote
Pace L, Klain M, Albanese C, Salvatore B, Storto G, Soricelli A, Salvatore M
* Short-term outcome of differentiated thyroid cancer patients receiving a second iodine-131 therapy on the basis of a detectable serum thyroglobulin level after initial treatment (532 views)
Eur J Nucl Med (ISSN: 1619-7070, 1619-7089, 0340-6997), 2006 Feb; 33(2): 179-183.
Impact Factor: 4.041
View Export to BibTeX Export to EndNote
Pace L, Klain M, Soricelli A, Albanese C, Salvatore B, Storto G, Salvatore M
* Short Term Outcome of Differentiated Thyroid Cancer Patients with Detectable Serum Thyroglobulin after Initial Treatment Receiving a Second 131-IODINE Therapy (522 views)
Eur J Nucl Med (ISSN: 1619-7070, 1619-7089, 0340-6997), 2005 Sep; 32: 179-183.
Impact Factor: 3.883
View Export to BibTeX Export to EndNote
Klain M, Pellegrino T, Storto G, Biondi B, Sansone V, Pagano L, Nicolai E, Della Morte A, D'Amico D, Soricelli A, Lombardi G, Pace L, Salvatore M
* Postsurgical follow up of differentiated thyroid cancer using rhTSH (378 views)
Eur J Nucl Med (ISSN: 1619-7070, 1619-7089, 0340-6997), 2004 Sep; 31: N/D-N/D.
Impact Factor: 3.935
View Export to BibTeX Export to EndNote
Biondi B, Palmieri EA, Pagano L, Klain M, Scherillo G, Salvatore M, Fenzi G, Lombardi G, Fazio S
* Cardiovascular safety of acute recombinant human thyrotropin administration to patients monitored for differentiated thyroid cancer (534 views)
J Clin Endocrinol Metab (ISSN: 0021-972x), 2003 Jan; 88(1): 211-214.
Impact Factor: 5.873
View Export to BibTeX Export to EndNote
16 Records (12 excluding Abstracts).
Total impact factor: 58.382 (40.153 excluding Abstracts).
Total 5 year impact factor: 51.662 (32.813 excluding Abstracts).
Total impact factor: 58.382 (40.153 excluding Abstracts).
Total 5 year impact factor: 51.662 (32.813 excluding Abstracts).
622 views. Last view on Wednesday 15 January 2025, 14:43:05
ibb.cnr.it
